ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A
Clinical trials for ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A explained in plain language.
Never miss a new study
Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A trials appear
Sign up with your email to follow new studies for ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a 'Priming' drug boost chemo for tough leukemia?
Disease control OngoingThis phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…
Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 20:01 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…
Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH T(9;11)(P21.3;Q23.3); MLLT3-KMT2A
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC